Adaptimmune starts SURPASS clinical trial with its first next-generation SPEAR T-cells
Adaptimmune Therapeutics and Oxfordshire has initiated SURPASS, its first clinical trial with a next-generation SPEAR T-cell targeting MAGE-A4. This next-generation SPEAR T-cell expresses the CD8α co-receptor alongside the engineered TCR that targets MAGE-A4. July 18, 2019